No phaseCompleted
Evaluate the Efficacy and Safety of LivPhcD Capsules in the NAFLD Subjects
Multi-center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of LivPhcD Capsules in the NAFLD Subjects
- Sponsor
- TCM Biotech International Corp. (Industry)
- Enrolment
- 110 enrolled
- Conditions
- NAFLD
- Interventions
- Placebo; 2 cap.LivPhcD/per day; 4 cap.LivPhcD/per day; 6 cap.LivPhcD/per day
- Ages
- adults, older adults
- Registry
- NCT05930093
Full record on ClinicalTrials.gov
From the registry
Non-alcoholic fatty liver disease (also called NAFLD) is a disease in which excessive fat accumulates in the liver of a patient without a history of alcohol abuse. Early-stage NAFLD does not usually cause any harm but nonalcoholic steatohepatitis (NASH) can lead to serious liver damage, including fibrosis or cirrhosis. Nearly 25% of the world's population is affected by NAFLD. There are no FDA-approved medications for the treatment of NAFLD currently and although lifestyle modifications with appropriate diet and exercise have been shown to be beneficial, this has been difficult to achieve and sustain for the majority of patients. LivPhcD™ capsule have shown hepatoprotective effects in both animal and human data. This study aims to investigate the effects of LivPhcD™ capsule in hepatocellular lipid content using Fibroscan.
Primary outcomes
- Reduction of Liver Fat
History
Last registry update
Study completion
Primary completion
Started
Registered